## Stefano Ghio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3285186/publications.pdf Version: 2024-02-01



STEEANO CHIO

#	Article	IF	CITATIONS
1	The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New England Journal of Medicine, 2005, 352, 1539-1549.	27.0	5,656
2	Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation, 2008, 117, 2608-2616.	1.6	1,878
3	Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. Journal of the American College of Cardiology, 2001, 37, 183-188.	2.8	1,151
4	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. Journal of the American College of Cardiology, 2008, 52, 1834-1843.	2.8	1,060
5	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	2.8	541
6	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	2.8	518
7	Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart, 2011, 97, 1675-1680.	2.9	479
8	Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. American Journal of Cardiology, 2000, 85, 837-842.	1.6	452
9	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H1373-H1381.	3.2	442
10	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	27.8	338
11	Pulmonary Vascular Hemodynamic Response to Exercise in Cardiopulmonary Diseases. Circulation, 2013, 128, 1470-1479.	1.6	319
12	Prevention of Disease Progression by Cardiac Resynchronization Therapy in Patients With Asymptomatic or Mildly Symptomatic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2009, 54, 1837-1846.	2.8	316
13	Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2010, 140, 272-278.	1.7	301
14	Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction. Circulation, 2013, 128, 502-511.	1.6	286
15	Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure. Circulation, 2012, 126, 822-829.	1.6	279
16	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
17	Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. European Heart Journal, 2004, 25, 571-578.	2.2	271
18	Association of galectinâ€3 and fibrosis markers with longâ€ŧerm cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CAREâ€HF (Cardiac Resynchronization in Heart Failure) trial. European Journal of Heart Failure, 2012, 14, 74-81.	7.1	203

#	Article	IF	CITATIONS
19	Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure. Circulation, 2009, 120, 1858-1865.	1.6	195
20	Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 873-879.	7.1	194
21	Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design. American Heart Journal, 2005, 149, 600-605.	2.7	192
22	Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response. Journal of the American College of Cardiology, 2008, 52, 438-445.	2.8	186
23	Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. European Heart Journal, 2009, 30, 2470-2477.	2.2	185
24	Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation, 2017, 136, 529-545.	1.6	182
25	Longâ€ŧerm left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CAREâ€HF trial. European Journal of Heart Failure, 2009, 11, 480-488.	7.1	167
26	Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. European Heart Journal, 2013, 34, 2592-2599.	2.2	150
27	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95.	27.8	148
28	Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient metaâ€analysis of longitudinal data (MeRGE Heart Failure). European Journal of Heart Failure, 2009, 11, 929-936.	7.1	146
29	Prognostic relevance of a nonâ€invasive evaluation of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 408-414.	7.1	132
30	Prognostic Relevance of Pulmonary Arterial Compliance in Patients With Chronic Heart Failure. Chest, 2014, 145, 1064-1070.	0.8	127
31	Echocardiography of Right Ventriculoarterial Coupling Combined With Cardiopulmonary Exercise Testing to Predict Outcome in Heart Failure. Chest, 2015, 148, 226-234.	0.8	123
32	Realâ€Time Threeâ€Dimensional Echocardiography Permits Quantification of Left Ventricular Mechanical Dyssynchrony and Predicts Acute Response to Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2008, 19, 392-399.	1.7	122
33	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
34	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
35	Predictors of clinical outcomes in elderly patients with heart failure. European Journal of Heart Failure, 2011, 13, 528-536.	7.1	109
36	Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction & & gt;35%: a PROSPECT trial substudy. European Journal of Heart Failure, 2010, 12, 581-587.	7.1	108

Stefano Ghio

#	Article	IF	CITATIONS
37	Reverse right ventricular remodeling after pulmonary endarterectomy. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 162-168.	0.8	103
38	Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal, 2006, 27, 562-568.	2.2	101
39	Clinical and Prognostic Relevance of Echocardiographic Evaluation of Right Ventricular Geometry in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2011, 107, 628-632.	1.6	94
40	Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation, 2017, 36, 166-174.	0.6	89
41	Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. European Heart Journal, 2009, 30, 2003-2010.	2.2	85
42	The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study. Heart Rhythm, 2015, 12, 524-530.	0.7	85
43	Characterization of <i>GDF2</i> Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
44	Effects of <i>n</i> â€3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSIâ€HF trial. European Journal of Heart Failure, 2010, 12, 1345-1353.	7.1	75
45	Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart, 2011, 97, 112-117.	2.9	74
46	Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 2153-2160.	2.8	74
47	Pulmonary Hypertension in HFpEFÂandÂHFrEF. Journal of the American College of Cardiology, 2020, 76, 1102-1111.	2.8	74
48	Left ventricular dyssynchrony assessed by two three-dimensional imaging modalities: phase analysis of gated myocardial perfusion SPECT and tri-plane tissue Doppler imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 166-173.	6.4	71
49	Real-Time Three-Dimensional Echocardiography as a Novel Approach to Quantify Left Ventricular Dyssynchrony: A Comparison Study with Phase Analysis of Cated Myocardial Perfusion Single Photon Emission Computed Tomography. Journal of the American Society of Echocardiography, 2008, 21, 801-807.	2.8	70
50	Cigarette Smoking and Hypertension Influence Nitric Oxide Release and Plasma Levels of Adhesion Molecules. Clinical Chemistry and Laboratory Medicine, 2001, 39, 822-6.	2.3	69
51	Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2064-2070.	2.0	68
52	Spinal cord stimulation for the treatment of refractory angina pectoris: A multicenter randomized single-blind study (the SCS-ITA trial). Pain, 2011, 152, 45-52.	4.2	67
53	Five-minute recording of heart rate variability in severe chronic heart failure: Correlates with right ventricular function and prognostic implications. American Heart Journal, 2000, 139, 1088-1095.	2.7	65
54	Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. American Heart Journal, 2003, 145, 310-316.	2.7	64

#	Article	IF	CITATIONS
55	Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leukemia Research, 2012, 36, e4-e6.	0.8	63
56	Real-time three-dimensional echocardiography as a novel approach to assess left ventricular and left atrium reverse remodeling and to predict response to cardiac resynchronization therapy. Heart Rhythm, 2008, 5, 1257-1264.	0.7	62
57	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. European Journal of Heart Failure, 2007, 9, 808-813.	7.1	61
58	Relevance of Echocardiographic Evaluation of Right Ventricular Function in Patients Undergoing Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1040-1049.	1.2	61
59	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Postâ€Hoc Analysis of the GISSIâ€HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq1	130778431	<b>∕5∎</b> gBT /Ove
60	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	2.2	51
61	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2013, 168, 1545-1547.	1.7	50
62	Stress Doppler Echocardiography in Systemic Sclerosis: Evidence for a Role in the Prediction of Pulmonary Hypertension. Arthritis and Rheumatism, 2013, 65, 2403-2411.	6.7	50
63	Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics. Journal of the American College of Cardiology, 2016, 68, 1037-1050.	2.8	50
64	Circulating biomarkers in pulmonary arterial hypertension: Update and future direction. Journal of Heart and Lung Transplantation, 2015, 34, 282-305.	0.6	49
65	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 365-375.	0.6	49
66	Effect of Transdermal Nitroglycerin or N-Acetylcysteine, or Both, in the Long-Term Treatment of Unstable Angina Pectoris. Journal of the American College of Cardiology, 1997, 29, 941-947.	2.8	48
67	Pulmonary arterial compliance: How and why should we measure it?. Global Cardiology Science & Practice, 2015, 2015, 58.	0.4	42
68	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000513.	6.7	42
69	Granulocyte function in coronary artery disease. American Journal of Cardiology, 1991, 68, B64-B68.	1.6	41
70	Validation of an echo-Doppler decision model to predict left ventricular filling pressure in patients with heart failure independently of ejection fraction. European Journal of Echocardiography, 2010, 11, 703-710.	2.3	41
71	Right ventricular recovery during followâ€up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2016, 18, 1462-1471.	7.1	41
72	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 484-492.	5.6	41

#	Article	lF	CITATIONS
73	Different susceptibility to the development of nitroglycerin tolerance in the arterial and venous circulation in humans. Effects of N-acetylcysteine administration Circulation, 1992, 86, 798-802.	1.6	39
74	Physiologic correlates of tricuspid annular plane systolic excursion in 1168 healthy subjects. International Journal of Cardiology, 2016, 223, 736-743.	1.7	39
75	Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. European Journal of Heart Failure, 2012, 14, 1420-1428.	7.1	37
76	Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. International Journal of Clinical Practice, 2013, 67, 656-664.	1.7	37
77	Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. Open Heart, 2016, 3, e000408.	2.3	36
78	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	6.2	36
79	Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities. American Heart Journal, 2017, 192, 120-127.	2.7	35
80	Usefulness and limits of transthoracic echocardiography in the evaluation of patients with primary and chronic thromboembolic pulmonary hypertension. Journal of the American Society of Echocardiography, 2002, 15, 1374-1380.	2.8	34
81	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With CardiacÂResynchronization. JACC: Heart Failure, 2017, 5, 169-178.	4.1	34
82	Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (CArdiac REsynchronisation Heart Failure study). European Journal of Echocardiography, 2006, 7, 373-378.	2.3	33
83	Clinical and angiographic findings in angina at rest. American Heart Journal, 1986, 111, 6-11.	2.7	32
84	Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2017, 230, 53-58.	1.7	32
85	Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in Northern Italy. Internal and Emergency Medicine, 2020, 15, 1457-1465.	2.0	32
86	Validation of Seattle Heart Failure Model for mortality risk prediction in patients treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 211-220.	7.1	29
87	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
88	Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. European Journal of Heart Failure, 2006, 8, 797-803.	7.1	28
89	Tumor Necrosis Factor-α Predicts Response to Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure. Circulation Journal, 2014, 78, 2232-2239.	1.6	28
90	Increased neutrophil aggregability in coronary artery disease. European Heart Journal, 1990, 11, 814-818.	2.2	27

#	Article	lF	CITATIONS
91	Impact of Ejection Fraction on the Clinical Response to Cardiac Resynchronization Therapy in Mild Heart Failure. Circulation: Heart Failure, 2013, 6, 1180-1189.	3.9	27
92	Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post apillary pulmonary hypertension. European Journal of Heart Failure, 2018, 20, 725-734.	7.1	27
93	Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760.	5.6	27
94	Tricuspid Annular Plane Systolic Excursion and Response to Cardiac Resynchronization Therapy: Results From the REVERSE Trial. Journal of Cardiac Failure, 2011, 17, 100-107.	1.7	26
95	Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients. International Journal of Cardiology, 2016, 224, 416-423.	1.7	26
96	Effects of diltiazem on regional coronary hemodynamics during atrial pacing in patients with stable exertional angina: implications for mechanism of action Circulation, 1986, 73, 1248-1253.	1.6	25
97	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure, 2012, 14, 946-953.	7.1	25
98	Pulmonary arterial compliance and exercise capacity after pulmonary endarterectomy. European Respiratory Journal, 2014, 43, 1403-1409.	6.7	25
99	Strengths and weaknesses of echocardiography for the diagnosis of pulmonary hypertension. International Journal of Cardiology, 2018, 263, 177-183.	1.7	25
100	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 1389-1397.	0.6	24
101	The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. European Journal of Clinical Investigation, 1999, 29, 1-5.	3.4	23
102	Doppler Velocimetry in Superior Vena Cava Provides Useful Information on the Right Circulatory Function in Patients with Congestive Heart Failure. Echocardiography, 2001, 18, 469-477.	0.9	23
103	Regional abnormalities of myocardial deformation in patients with hypertrophic cardiomyopathy: correlations with delayed enhancement in cardiac magnetic resonance. European Journal of Heart Failure, 2009, 11, 952-957.	7.1	23
104	Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). Journal of the American Heart Association, 2015, 4, e002054.	3.7	23
105	Echocardiography and Heart Failure: A Glimpse of the Right Heart. Echocardiography, 2015, 32, S95-107.	0.9	23
106	Echocardiographic Dyssynchrony and Health Status Outcomes From Cardiac Resynchronization Therapy. JACC: Cardiovascular Imaging, 2010, 3, 451-460.	5.3	22
107	Mitral and aortic valve sclerosis/calcification and carotid atherosclerosis: results from 1065 patients. Heart and Vessels, 2014, 29, 776-783.	1.2	22
108	The determinants of clinical outcome and clinical response to CRT are not the same. Heart Failure Reviews, 2012, 17, 755-766.	3.9	21

#	Article	IF	CITATIONS
109	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	12.8	21
110	A Comparison of Evaporative and Conventional Freezing Prior to Freeze-Drying of Fruits and Vegetables. Food and Bioproducts Processing, 2000, 78, 187-192.	3.6	20
111	Pulmonary Hypertension in Advanced Heart Failure. Herz, 2005, 30, 311-317.	1.1	17
112	Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2 pulmonary) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 5 17
113	Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony?. European Heart Journal, 2003, 24, 384-390.	2.2	16
114	Left atrial dilatation in systolic heart failure: a marker of poor prognosis, not just a buffer between the left ventricle and pulmonary circulation. Journal of Echocardiography, 2018, 16, 155-161.	0.8	16
115	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension. Journal of Cardiovascular Medicine, 2018, 19, 12-17.	1.5	16
116	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 633-642.	1.5	16
117	Firstâ€inâ€man case of nonâ€invasive proton radiotherapy for the treatment of refractory ventricular tachycardia in advanced heart failure. European Journal of Heart Failure, 2021, 23, 195-196.	7.1	16
118	Undiagnosed connective tissue diseases. Medicine (United States), 2016, 95, e4827.	1.0	15
119	Long-term reverse remodeling by cardiac resynchronization therapy with MultiPoint Pacing: A feasibility study of noninvasive hemodynamics–guided device programming. Heart Rhythm, 2018, 15, 1766-1774.	0.7	15
120	The Right Heart International Network (RIGHT-NET). Heart Failure Clinics, 2018, 14, 443-465.	2.1	15
121	Early readmission for heart failure: An avoidable or ineluctable debacle?. International Journal of Cardiology, 2019, 277, 186-195.	1.7	15
122	Right Ventricular Functional Reserve in Early-Stage Idiopathic Pulmonary Fibrosis. Chest, 2019, 155, 297-306.	0.8	15
123	Prognostic Significance of an Early Echocardiographic Evaluation of Right Ventricular Dimension and Function in Acute Heart Failure. Journal of Cardiac Failure, 2020, 26, 813-820.	1.7	15
124	Long-term survival and risk stratification in patients with angina at rest undergoing medical treatment. International Journal of Cardiology, 1989, 22, 43-50.	1.7	14
125	Relationship between electrocardiographic findings and Cardiac Magnetic Resonance phenotypes in patients with Hypertrophic Cardiomyopathy. IJC Heart and Vasculature, 2016, 11, 7-11.	1.1	14
126	The prognostic impact of diastolic dysfunction in patients with chronic heart failure and post-acute myocardial infarction: Can age-stratified E/A ratio alone predict survival?. International Journal of Cardiology, 2015, 181, 362-368.	1.7	13

#	Article	IF	CITATIONS
127	Changes in surface electrocardiogram in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy. Correlations with hemodynamic and echocardiographic improvements after surgery. Journal of Electrocardiology, 2016, 49, 223-230.	0.9	13
128	Effects of maternal stress and cortisol exposure atÂtheÂegg stage on learning, boldness andÂneophobiaÂinÂbrookÂtrout. Behaviour, 2016, 153, 1639-1663.	0.8	13
129	Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension. PLoS ONE, 2017, 12, e0188383.	2.5	13
130	Effects of cold stimulation on coronary haemodynamics during exercise in patients with coronaryartery diseas. European Heart Journal, 1985, 6, 239-246.	2.2	12
131	Coronary haemodynamic effects of short-term intravenous administration of gallopamil in patients with stable exertional angina Heart, 1987, 57, 226-231.	2.9	12
132	Pulmonary endarterectomy in the elderly. Journal of Cardiovascular Medicine, 2016, 17, 144-151.	1.5	12
133	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. Heart Failure Reviews, 2020, 25, 85-91.	3.9	12
134	Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. Progress in Cardiovascular Diseases, 2021, 67, 89-97.	3.1	12
135	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Annals of Thoracic Medicine, 2014, 9, 1.	1.8	11
136	MitraClip procedure as â€~bridge to list', the ultimate therapeutic option for endâ€stage heart failure patients not eligible for heart transplantation due to severe pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-4.	1.7	11
137	Dobutamine stress echocardiography in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 270, 331-335.	1.7	11
138	QTc Interval and Mortality in a Population of SARS-2-CoV Infected Patients. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008890.	4.8	11
139	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 1080-1090.	7.1	11
140	Morphologic changes induced by acetylcholine infusion in normal and atherosclerotic coronary arteries. American Journal of Cardiology, 1993, 71, 1382-1390.	1.6	10
141	Enoximone echocardiography: a novel test to evaluate left ventricular contractile reserve in patients with heart failure on chronic beta-blocker therapy. Cardiovascular Ultrasound, 2003, 1, 13.	1.6	10
142	Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. International Journal of Cardiology, 2018, 271, 301-305.	1.7	10
143	Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH). European Radiology, 2021, 31, 6230-6238.	4.5	10
144	Pulmonary endarterectomy in the octogenarian population: safety and outcomes. Journal of Cardiovascular Medicine, 2021, 22, 567-571.	1.5	10

#	Article	IF	CITATIONS
145	Analyses of Longitudinal and of Transverse Right Ventricular Function Provide Different Clinical Information in Patients with Pulmonary Hypertension. Ultrasound in Medicine and Biology, 2014, 40, 1096-1103.	1.5	9
146	More on the right ventricle in pulmonary hypertension. European Respiratory Journal, 2015, 45, 33-35.	6.7	9
147	Women with nonischemic cardiomyopathy have a favorable prognosis and a better left ventricular remodeling than men after cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2016, 17, 291-298.	1.5	9
148	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.6	9
149	Relationship Between Acute Improvement in Left Ventricular Function to 6-Month Outcomes After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure. Congestive Heart Failure, 2011, 17, 64-69.	2.0	8
150	Iron deficiency in pulmonary arterial hypertension: prevalence and potential usefulness of oral supplementation. Acta Cardiologica, 2021, 76, 162-167.	0.9	8
151	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. European Respiratory Journal, 2022, 60, 2102276.	6.7	8
152	The Tailored Medical Therapy in Patients With Advanced Heart Failure Referred for Cardiac Transplantation. Transplantation Proceedings, 2008, 40, 1999-2000.	0.6	7
153	Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma. Case Reports in Oncology, 2011, 4, 487-489.	0.7	7
154	Severe aortic valve stenosis with normal left ventricular function and low vs. high pressure gradient: Different hemodynamic profiles but similar clinical presentation, comorbidity and outcome. International Journal of Cardiology, 2013, 167, 2326-2328.	1.7	7
155	â€~Real-life' information on pulmonary arterial hypertension: the iPHnet Project. Current Medical Research and Opinion, 2014, 30, 2409-2414.	1.9	7
156	Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease. Annals of Thoracic Medicine, 2014, 9, 47.	1.8	7
157	Persistent exercise limitation after successful pulmonary endoarterectomy: frequency and determinants. Respiratory Research, 2019, 20, 34.	3.6	7
158	Risk stratification in patients with residual pulmonary hypertension after pulmonary endarterectomy. International Journal of Cardiology, 2021, 334, 116-122.	1.7	7
159	Haemodynamic impact of MitraClip in patients with functional mitral regurgitation and pulmonary hypertension. European Journal of Clinical Investigation, 2021, 51, e13676.	3.4	7
160	A multicentric quality-control study of exercise Doppler echocardiography of the right heart and the pulmonary circulation. The RIGHT Heart International NETwork (RIGHT-NET). Cardiovascular Ultrasound, 2021, 19, 9.	1.6	7
161	Results of the Predictors of Response to Cardiac Resynchronization Therapy (PROSPECT) Trial. Journal of Cardiac Failure, 2007, 13, 793.	1.7	6
162	Right ventricular total isovolumic time: Reference value study. Echocardiography, 2019, 36, 1234-1240.	0.9	6

4

#	Article	IF	CITATIONS
163	Additive Value of Biomarkers and Echocardiography to Stratify the Risk of Death in Heart Failure Patients with Reduced Ejection Fraction. Cardiology Research and Practice, 2019, 2019, 1-9.	1.1	6
164	Incidence of appropriate anti-tachycardia therapies after elective generator replacement in patient with heart failure initially implanted with a defibrillator for primary prevention: Results of a meta-analysis. International Journal of Cardiology, 2019, 283, 122-127.	1.7	6
165	Feasibility of semi-recumbent bicycle exercise Doppler echocardiography for the evaluation of the right heart and pulmonary circulation unit in different clinical conditions: the RIGHT heart international NETwork (RIGHT-NET). International Journal of Cardiovascular Imaging, 2021, 37, 2151-2167.	1.5	6
166	Is it time for a paradigm shift: Should doubleâ€lung transplant be considered the treatment of choice for idiopathic pulmonary arterial hypertension and giant pulmonary aneurysm?. Journal of Cardiac Surgery, 2021, 36, 2996-2999.	0.7	6
167	Effects of atrial pacing and dipyridamole administration on coronary hemodynamics of collateralized myocardial regions in stable angina pectoris. American Journal of Cardiology, 1990, 65, 703-708.	1.6	5
168	Rescreening of ?healthy? relatives of patients with dilated cardiomyopathy identifies subgroups at risk of developing the disease. European Heart Journal Supplements, 2004, 6, F54-F60.	0.1	5
169	Aortic valve sclerosis is a marker of atherosclerosis independently of traditional clinical risk factors. Analysis in 712 patients without ischemic heart disease. International Journal of Cardiology, 2012, 158, 163-164.	1.7	5
170	The Impact of the PR Interval in PatientsÂReceiving Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2017, 3, 818-826.	3.2	5
171	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. Pulmonary Circulation, 2020, 10, 204589402096383.	1.7	5
172	Prognostic relevance of Doppler echocardiographic re-assessment in HFrEF patients. International Journal of Cardiology, 2021, 327, 111-116.	1.7	5
173	Right ventricular dysfunction in advanced heart failure. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 852-5.	0.1	5
174	Acute haemodynamic effects of diltiazem in patients with recent Q-wave myocardial infarction. European Heart Journal, 1988, 9, 740-745.	2.2	4
175	Role of echo Doppler techniques in the evaluation and treatment of heart failure patients. Country Review Ukraine, 2006, 8, E28-E31.	0.8	4
176	Baseline and 6-month B-type natriuretic peptide changes are independent predictors of events in patients with advanced heart failure awaiting cardiac transplantation. Journal of Cardiovascular Medicine, 2009, 10, 671-676.	1.5	4
177	Cumulative analysis on 4802 patients confirming that women benefit more than men from cardiac resynchronization therapy. International Journal of Cardiology, 2015, 182, 454-456.	1.7	4
178	Multipoint Pacing versus conventional ICD in Patients with a Narrow QRS complex (MPP Narrow QRS) Tj ETQq0 (	0 0 rgBT /( 1.0	Overlock 10 T
179	Different forms of pulmonary hypertension in a family with clinical and genetic evidence for hereditary hemorrhagic teleangectasia type 2. Pulmonary Circulation, 2018, 8, 1-4.	1.7	4

180Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension.<br/>Diagnostics, 2020, 10, 857.2.6

#	Article	lF	CITATIONS
181	Long-Term Effects of the Replacement of Calcineurin Inhibitors With Everolimus and Mycophenolate in Patients With Calcineurin Inhibitor–Related Nephrotoxicity. Transplantation Proceedings, 2020, 52, 836-842.	0.6	4
182	BMPR2Âmutations and response to inhaled or parenteral prostanoids: a case series. Pulmonary Circulation, 2021, 11, 1-5.	1.7	4
183	Nonresponse to Acute Vasodilator Challenge and Prognosis in Heart Failure With Pulmonary Hypertension. Journal of Cardiac Failure, 2021, 27, 869-876.	1.7	4
184	High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis?. Journal of Cardiovascular Medicine, 2021, 22, 828-831.	1.5	4
185	Management of Crescendo Angina. European Heart Journal, 1985, 6, 83-86.	2.2	3
186	Hyperventilation-induced coronary vasospasm refractory to intracoronary nitroglycerin. American Heart Journal, 1990, 119, 957-960.	2.7	3
187	Clinical Evaluation of Calcium-Antagonist Drugs. Journal of Cardiovascular Pharmacology, 1992, 20, S71-S74.	1.9	3
188	Hemodynamic changes before acute heart failure episodes in patients with advanced systolic left ventricular dysfunction. Journal of Cardiovascular Medicine, 2008, 9, 799-804.	1.5	3
189	Pulmonary hypertension in left heart disease: The need to continue to explore. International Journal of Cardiology, 2019, 288, 132-134.	1.7	3
190	The prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy: An updated meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 1902-1905.	1.8	3
191	Is the fear of COVID-19 infection the same in all subjects?. International Journal of Infectious Diseases, 2020, 97, 331-333.	3.3	3
192	Magnetic resonance imaging of pulmonary arterial compliance after pulmonary endarterectomy. European Respiratory Journal, 2020, 55, 1902171.	6.7	3
193	Incidence of Ventricular Arrhythmias and 1â€Year Predictors of Mortality in Patients Treated With Implantable Cardioverterâ€Defibrillator Undergoing Generator Replacement. Journal of the American Heart Association, 2021, 10, e018090.	3.7	3
194	QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. Journal of Cardiovascular Medicine, 2022, 23, e21-e23.	1.5	3
195	Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 929-936.	1.5	3
196	Coronary vasoconstrictor response to cold pressor test in variant angina: Lack of relation to intracoronary thromboxane concentrations. American Heart Journal, 1987, 114, 511-515.	2.7	2
197	Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans. Cardiovascular Drugs and Therapy, 1992, 6, 255-259.	2.6	2
198	Cardiac Resynchronization Therapy in Patients with Left Ventricular Ejection Fraction Above 35%. Journal of Cardiac Failure, 2009, 15, S62.	1.7	2

Stefano Ghio

#	Article	IF	CITATIONS
199	Papel de la ecocardiografÃa en la selección de los pacientes que responden a la terapia de resincronización cardiaca tras el estudio PROSPECT. Revista Espanola De Cardiologia, 2009, 62, 843-846.	1.2	2
200	Riociguat for HF with Pulmonary Hypertension (PH): Post-hoc Analysis of LEPHT by Baseline Pulmonary Vascular Resistance (PVR) and Pulmonary Vascular Gradient (PVG). Journal of Cardiac Failure, 2014, 20, S9.	1.7	2
201	Echo and BNP serial assessment in ambulatory heart failure care: Data on loop diuretic use and renal function. Data in Brief, 2016, 9, 1074-1076.	1.0	2
202	Invasive and Noninvasive Evaluation for the Diagnosis of Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 353-360.	2.1	2
203	Similar predictive value of six-minute walking distance and B-type natriuretic peptide in heart failure with reduced to mid-range ejection fraction. Monaldi Archives for Chest Disease, 2019, 89, .	0.6	2
204	Pulmonary Artery Wedge Pressure Respiratory Variation Increases With Sodium Nitroprusside Vasodilator Challenge. Journal of Cardiac Failure, 2020, 26, 1096-1099.	1.7	2
205	Pathophysiology, Clinical Presentation, and Prognosis of Angina Pectoris. Developments in Cardiovascular Medicine, 1994, , 3-11.	0.1	2
206	Increased coronary tone in exertional angina: The beneficial effects of calcium antagonists. Cardiovascular Drugs and Therapy, 1990, 4, 893-897.	2.6	1
207	Variable response to atrial pacing after intravenous propranolol in patients with stable exertional angina. European Heart Journal, 1990, 11, 997-1005.	2.2	1
208	Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. European Heart Journal Supplements, 2004, 6, F35-F39.	0.1	1
209	The evaluation of right ventricular performance in different clinical models of heart failure. European Heart Journal Supplements, 2004, 6, F61-F67.	0.1	1
210	Change in plasma brain natriuretic peptide is a strong predictor of prognosis in patients with advanced heart failure awaiting for cardiac transplantation. Journal of Heart and Lung Transplantation, 2005, 24, S131.	0.6	1
211	Corrigendum to: 'Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy'. European Heart Journal, 2006, 27, 1760-1760.	2.2	1
212	Role of Cardiac Ultrasound in Selecting Patients Who Respond to Cardiac Resynchronization Therapy in the Light of the PROSPECT Study. Revista Espanola De Cardiologia (English Ed ), 2009, 62, 843-846.	0.6	1
213	Corrigendum to â€ <sup>-</sup> Effects of n -3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial' [Eur J Heart Fail 2010;12:1345-1353]. European Journal of Heart Failure, 2011, 13, 1042-1042.	7.1	1
214	Prognostic Implications of Left Ventricular Dilation in Patients With Nonischemic Heart Failure: Interactions With Restrictive Filling Pattern and Mitral Regurgitation. Congestive Heart Failure, 2012, 18, 198-204.	2.0	1
215	Mode of Death in Patients with Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2013, 32, S17-S18.	0.6	1
216	Prognostic stratification of patients with chronic systolic heart failure using biomarkers and Doppler echocardiography. Journal of Cardiovascular Medicine, 2014, 15, 470-475.	1.5	1

#	Article	IF	CITATIONS
217	Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2036-2040.	2.6	1
218	Out-of-hospital cardiac arrest in patients with heart disease from family members' perspective: high perception of risk, low sense of adequacy and the importance of training. Journal of Cardiovascular Medicine, 2021, 22, 790-791.	1.5	1
219	Acute Pericarditis, Graves' Disease and Thymic Hyperplasia—A Case Report. European Heart Journal - Case Reports, 2021, 5, ytab392.	0.6	1
220	Prognostic impact of diabetes in chronic and acute heart failure. Heart Failure Reviews, 2021, , 1.	3.9	1
221	The haemodynamic assessment of patients with pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202004.	0.4	1
222	Response to acute vasodilator challenge and haemodynamic modifications after MitraClip in patients with functional mitral regurgitation and pulmonary hypertension. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 464-469.	1.0	1
223	When you hear hoofbeats, think zebras ―pulmonary venoâ€occlusive disease: a case report. Pulmonary Circulation, 0, , .	1.7	1
224	Effects of surgical versus medical treatment of long-term prognosis in angina at rest: an observational non-randomized study of 400 patients. European Heart Journal, 1988, 9, 513-519.	2.2	0
225	Tissue Doppler and cardiac resynchronisation therapy: a new challenge for the optimal choice of candidates: Reply. European Heart Journal, 2004, 25, 1363-1364.	2.2	0
226	The Prognostic Power of Mitral Filling Pattern: Is it the same in all Patients? Results From an Individual Patient Meta-Analysis (MeRGE). Heart Lung and Circulation, 2008, 17, S86.	0.4	0
227	235: Baseline and 6 Months B-Type Natriuretic Peptide Changes Are Independent Predictors of Events in Patients with Advanced Heart Failure Awaiting for Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, S145.	0.6	0
228	Relationship of pulmonary hypertension and right ventricular dysfunction with survival of elderly patients with chronic systolic heart failure. European Heart Journal, 2013, 34, 3630-3630.	2.2	0
229	SAT0435â€Undiagnosed Connective Tissue Diseases in Pulmonary Arterial Hypertension Patients: Baseline and Follow-Up Results from a PAH Referral Centre. Annals of the Rheumatic Diseases, 2015, 74, 817.2-817.	0.9	0
230	SAT0225â€Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis Patients: Single Center Real-Life Performance of The Detect Algorithm. Annals of the Rheumatic Diseases, 2016, 75, 749.4-750.	0.9	0
231	The need for evaluating right ventricular adaptation and ventriculo–arterial coupling: reply. European Journal of Heart Failure, 2018, 20, 944-945.	7.1	0
232	Initial combination therapy for patients with pulmonary arterial hypertension (PAH): a budget impact analysis from the perspective of the Italian national healthcare system. Expert Opinion on Orphan Drugs, 2018, 6, 1-7.	0.8	0
233	EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2018, 154, 1062A-1064A.	0.8	0
234	Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 525-526.	5.6	0

#	Article	IF	CITATIONS
235	Left-Heart Failure and Its Effects on the Right Heart. , 2021, , 157-162.		0
236	Right ventricular time intervals – Comparison between pulsed wave Doppler and tissue Doppler imaging. Echocardiography, 2021, 38, 1762-1768.	0.9	0
237	Echocardiographic evolution of left ventricular and left atrial thrombi in a patient with left ventricular dysfunction due to acoholic cardiomyopathy, chronic fibrillation and multiple non-fatal systemic embolisms. Acta Cardiologica, 2001, 56, 131-135.	0.9	0
238	124 Recovery of right ventricular function and clinical improvement in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy. European Journal of Heart Failure, Supplement, 2007, 6, 30-31.	0.0	0
239	129 A characteristic and potentially diagnostic abnormality of systolic myocardial deformation at Doppler myocardial imaging in patients with hypertrophic cardiomyopathy. European Journal of Heart Failure, Supplement, 2007, 6, 32-32.	0.0	0
240	257 Different prognostic relevance of left ventricular volumes and ejection fraction in heart failure patients with ischemic or non ischemic aetiology: a meta analysis. European Journal of Heart Failure, Supplement, 2007, 6, 51-51.	0.0	0
241	Cardiac dystrophinopathies: prevalence and clinical phenotypes in a consecutive series of 408 males with idiopathic dilated cardiomyopathy. European Journal of Heart Failure, Supplement, 2008, 7, 53-53.	0.0	0
242	Left Heart Failure. , 2014, , 209-221.		0
243	Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1. , 2015, , .		0
244	Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study. , 2015, , .		0
245	Ambrisentan and tadalafil as initial combination therapy for pulmonary arterial hypertension: clinical effect and haemodynamic changes. An Italian multicenter retrospective analysis. , 2017, , .		0
246	Persistent exercise limitation after successful pulmonary endoarterectomy: frequency and determinants. , 2018, , .		0
247	The haemodynamic assessment of patients with pulmonary arterial hypertension. Global Cardiology Science & Practice, 2020, 2020, e202004.	0.4	0
248	Surgical management of pulmonary endarterectomy avoiding deep hypothermia: the Pavia experience. Annals of Cardiothoracic Surgery, 2021, 11, 0-0.	1.7	0
249	Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial. , 2020, , .		0
250	Effects of intra-aortic balloon pump on myocardial efficiency in a patient with advanced heart failure: non-invasive assessment with pressure–strain analysis. European Heart Journal Cardiovascular Imaging, 2022, 23, e88-e88.	1.2	0
251	Gaps of evidence in pulmonary arterial hypertension. International Journal of Cardiology, 2022, , .	1.7	0